Moreover, adiponectin revealed as a potential biological marker for restenosis in T2DM patients and, in this sense, it has been tried to find a possible cut-off (plasma adiponectin levels ≥ 6.0 μg/mL) associated with a lower risk of restenosis both in diabetic and non-diabetic subjects [44]. Here, ADIPOQ is linked to type 2 diabetes mellitus.